Explore the latest approaches to treating Hepatitis B in this comprehensive lecture from the UCLA Mellinkoff Gastroenterology and Hepatology Symposium. Delve into the global impact of Hepatitis B, its progression, and diagnostic methods using serum markers. Examine FDA-approved therapies for chronic HBV and learn about treatment criteria for various stages of the disease, including HBeAg positive and negative chronic hepatitis B, as well as compensated cirrhosis. Discover the endpoints of antiviral therapy and compare treatment options based on their effectiveness in HBV DNA loss. Gain insights into the US treatment algorithm and understand why first-line treatment options have the lowest resistance rates. This informative presentation by Dr. Steven-Huy Han provides valuable knowledge for healthcare professionals dealing with Hepatitis B management.
Treating Hepatitis B - Steven-Huy Han, MD - UCLA Digestive Diseases
University of California, Los Angeles via YouTube
Overview
Syllabus
Intro
Hepatitis B is a Devastating Global Healthcare Issue
Where Are the Long-term HBV Carriers?
Progression of Hepatitis B Infection
Diagnosis of HBV Infection: Using Serum Markers
FDA Approved Therapies for Chronic HBV
Treatment Criteria for Chronic Hepatitis B
Indications for antiviral therapy HBeAg Positive CHB
Indications for antiviral therapy HBeAg Negative CHB
Indications for antiviral therapy Compensated Cirrhosis
Endpoints of antiviral therapy HBeAg Positive CHB
HBeAg-Positive CHB Treatment Options: HBV DNA Loss at 1 Year
US Treatment Algorithm - Resistance Profile: First Line Treatment Options Have The Lowest Resistance Rates
Taught by
UCLA Health
